Program
prulacabtagene leucel
Its studies are mostly in Lupus Nephritis · Arthritis, Rheumatoid, led by Adicet Therapeutics.
Furthest: phase 1, since Apr 17, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Adicet Therapeutics | 22 open or running | phase 1since Apr 17, 2024 | Apr 17, 2024 | Dec 2026phase 1 · NCT06375993 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2024First study: phase 1 study in Lupus NephritisFirst studyNCT06375993 · 180 planned · United States
- Jul 28, 2025Phase 1 study in Arthritis, RheumatoidNCT07100873 · 25 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in Lupus NephritisNCT06375993
- Mar 30, 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07100873
TargetBeta
MS4A1 →read by rule
“A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), ”NCIt, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| ocrelizumabrule | Hoffmann-La Roche | phase 4 | 42 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07100873Arthritis, Rheumatoid · China | 1 | Recruiting | Mar 30, 2027 | 25 |
| NCT06375993Lupus Nephritis · United States | 1 | By invitation | Dec 2026 | 180 |
How it is read
Names in the registry
- “ADI-001”, 2 entries
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.